### 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki, H., Nishizawa, T., Tsugawa, H., Mogam i, S., Hibi, T.	Roles of oxidative stres s in stomach disorders.	J. Clin. Biochem. Nutr.	50(1)	35-39	2012.
Iwasaki, E., <u>Suzu</u> ki, H., Masaoka, T., Nishizawa, T., Hosoda, H., Kangawa, K., Hibi, T.	Enhanced gastric ghreli n production and secret ion in rats with gastric outlet obstruction.	Dig. Dis. Sci.	57(4)	858-864	2012
Mogami, S., Suzuk <u>i, H.,</u> Fukuhara, S., Matsuzaki, J., Kangawa, K., Hibi, T.	Reduced ghrelin production induced anorexia a fter rat gastric ischemia and reperfusion.	Am. J. Physiol. Gastrointest. Liver Physiol.	302(3)	G359-64	2012
Nishizawa, T., <u>Suzuki,</u> <u>H.</u> , Suzuki, M., Takahash i, M., Hibi, T. et al.	PPI-amoxicillin-clarithro mycin versus PPI-amox icillin-metronidazole as first-line <i>Helicobacter p ylori</i> eradication therapy.	J. Clin. Biochem. Nutr.	51(2)	114-6	2012
Matsuzaki, J., <u>Suzuki,</u> <u>H.</u> , Nishizawa, T., Hirata, K., Tsugawa, H., Saito, Y., Okada, S., Fukuhara, S., Hibi, T.	Efficacy of sitafloxacin- based rescue therapy fo r <i>Helicobacter pylori</i> af ter failures of first- and second-line therapies.	Antimicrob. Agent Chemother.	56(3)	1643-45	2012
Kobayashi, S., Okamura, Y., Suzuki, H., Taniki, N., Uehara, J., Ojiro, K., Teramoto, K., Kurinoki, M., Chigusa, Y., Shiwak u, K., Hibi, T.	Capsule endoscopy assi sts in the complete de worming of parasites.	J. Gastroenterol. Hepatol.	27	1253	2012
Matsuzaki, J., <u>Suzuki,</u> <u>H.</u> , Asakura, K., Fukushi ma, Y., Inadomi, J.M., T akebayashi, T., Hibi, T.	Classification of functio nal dyspepsia based on concomitant bowel sy mptoms.	Neuro- gastroenterol. Motil.	24(4)	325-e164	2012
sugawa, H., <u>Suzuki, H.</u> , Matsuzaki, J., Hirata, K., Hibi, T.	FecA1, a bacterial iron transporter, determines the survival of <i>Helico bacter pylori</i> in the sto mach.	Free Radic. Biol. Med.	52(6)	1013-1010	2012
Asano, T., Tanaka, K., S uemasu, S., Ishihara, T., Tahara, K., Suzuki, T., <u>S</u> <u>uzuki, H.</u> , Fukudo, S., M izushima, T.	Effects of β-(1,3-1,6)-D -glucan on irritable bo wel syndrome-related c olonic hypersensitivity.	Biochem. Biophys. Res. Com.	420(2)	444-9	2012

Nishizawa, T., Suzuki, H., Maekawa, T., Harada, N., Toyokawa, T., Kuwa i, T., Ohara, M., Suzuki, T., Kawanishi, M., Nog uchi, K., Yoshio, T., Kat sushima, S., Tsuruta, H., Eiji Masuda, E., Tanaka, M., Katayama, S., Kawa mura, N., Nishizawa, Y., Hibi, T., Takahashi, M.	Dual therapy for third-line <i>H. pylori</i> eradication and urea breath test prediction.	World J. Gastroenterol.	18(21)	2735-2738	2012
Fukushima, Y., Suzuki, H., Matsuzaki, J., Kiyosu e, A., Hibi, T.	Efficacy of solifenacin on irritable bowel synd rome with diarrhea (IB S-D): open-label prospective pilot trial.	J. Neuro- gastroenterol. Motil.	18(3)	317-323	2012
Matsuzaki, J., <u>Suzuki,</u> <u>H.</u> , Fukushima, Y., Hirat a, K., Fukuhara, S., Okad a, S., Hibi, T.	High frequency of over lap between functional dyspepsia and overactive bladder.	Neuro- gastroenterol. Motil.	24(9)	821-7	2012
Nakamizo, H., Suzuki, H., Miura, S., Mogami, S., Kishikawa, H., Yoshid a, H., Matsui, H., Hibi, T.	Transmural pressure loa ding enhances gastric mucosal proliferation.	Dig. Dis. Sci.	57(10)	2545-2554	2012
Naito, Y., Uchiyama, K., Kinoshita, Y., Fukudo, S., Joh, T., Suzuki, H., Takahashi, S., Ueno, F., Fujiwara, Y., Arakawa, T., Matsumoto, T., Hah m, K.B., Kachintorn, U., Syam A.F., Rani, A.A., Sollano, J.D., Zhu, Q.	A Questionnaire-Based Survey on Screening fo r gastric and colorectal cancer by physicians i n East Asian countries in 2010.	Digestion	86(2)	94-106	2012
Ishimura, N., Amano, Y., Sollano, J.D., Zhu, Q., Kachintorn, U., Rani, A. A., Hahm, K-B., Takahas hi, S., Arakawa, T., Joh, T., Matsumoto, T., Naito, Y., Suzuki, H., Ueno, F., Fukudo, S., Fujiwara, Y., Kamiya, T., Uchiyam a, K., Kinoshita, Y., The IGICS Study Group.	Questionnaire-based sur vey conducted in 2011 concerning endoscopic management of Barret t's esophagus in East Asian countries.	Digestion	86(2)	136-146	2012
Yahiro, K., Satoh, M., N akano, M., Hisatune, J., I somoto, H., Sap, J., Suzuki, H., Nomura, F., Noda, M., Moss, J., Hirayama, T.	Low-density lipoprotein receptor-related protein -1 (LRP-1) mediates au tophagy and apoptosis caused by <i>Helicobacter pylori</i> VacA.	J. Biol. Chem.	287(37)	31104-15	2012
Nakashita, M., <u>Suzuki,</u> <u>H.</u> , Miura, S., Taki, T., Uehara, K., Mizushima, T., Nagata, H., Hibi, T.	Attenuation of acetic a cid-induced gastric ulce r formation in rats by glucosylceramide syntha se inhibitors.	Dig. Dis. Sci.	58(2)	354-62	2013

Saito, Y., Suzuki, H., Ta ya, T., Nishizawa, M., Ts ugawa, H., Matsuzaki, J., Hirata, K., Saito, H., Hi bi, T.	Development of a nove l microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs.	Biochem. Biophys. Res. Com.	426(1)	33-37	2012
Suzuki, H., Matsuzaki, J.	Are solifenacin and ra mosetron really ideal to treat irritable bowel s yndrome?: Author's Reply.	J. Neuro- gastroenterol. Motil.	18(4)	459	2012
Saito, Y., Suzuki, H., Im aeda, H., Matsuzaki, J., Hirata, K., Tsugawa, H., Hibino, S., Kanai, Y., Sai to, H., Hibi, T.	The tumor suppressor <i>microRNA-29c</i> is downr egulated and restored by celecoxib in human gastric cancer cells.	Int. J. Cancer	132(8)	1751-60	2013
Saito, Y., Suzuki, H., Ts ugawa, H., Imaeda, H., Matsuzaki, J., Hirata, K., Hosoe, N., Nakamura, M., Hosoe, N., Saito, H., Hibi, T.	Overexpression of <i>miR-142-5p</i> and <i>miR-155</i> in gastric mucosa-associat ed lymphoid tissue (M ALT) lymphoma resista nt to <i>Helicobacter pylo ri</i> eradication.	PLoS One	7(11)	e47396	2012
Suemasu, S., Yamakawa, N., Ishihara, T., Asano, T., Tahara, K., Tanaka, K., Matsui, H., Okamoto, Y., Otsuka, M., Takeuch i, K., Suzuki, H., Mizush ima, T.	Identification of unique NSAID, fluoro-loxopro fen with gastroprotective activity.	Biochem. Pharmacol.	84(11)	1470-81	2012
Hirano, Y., Takeuchi, H., Oyama, T., Saikawa, Y., Niihara, M., Sako, H., Omagari, K., Nishi, T., <u>S</u> <u>uzuki, H.</u> , Hibi, T., Kita gawa, Y.	Minimally invasive sur gery for esophageal epi phrenic diverticulum – the results of our experience and 133 patients in 25 published series.	Surgery Today	43(1)	1-7	2013
Suzuki, H., Nishizawa, T., Tsugawa, H., Hibi, T.	Molecular approaches a nd modern clinical strat egies for the managem ent of <i>Helicobacter pyl ori</i> infection in Japan.	Keio J. Med.	61(4)	109-119	2012
Iwasaki, E., Suzuki, H., Mogami, S., Hibi, T. Enh anced gastric ghrelin indu ced c-kit protein expressi on in rats with gastric ou tlet obstruction.	Enhanced gastric ghreli n induced c-kit protein expression in rats wit h gastric outlet obstruct ion.	Dig. Dis. Sci.	57(12)	3308-3309	2012

Nishizawa, T., <u>Suzuki,</u> <u>H.</u> , Takahashi, M., Kanek o, H., Suzuki, M., Hibi, T.	Effect of ursodeoxychol ic acid and endoscopic sphincterotomy in lon g-term stenting for common bile duct stones.	J. Gastroenterol. Hepatol.	28(1)	63-7	2013
Tsugawa, H., Suzuki, H., Saya, H., Hatakeyama, M., Hirayama, T., Hirata, K., Nagano, O., Matsuza ki, J., Hibi, T.	Helicobacter pylori Cag A degradation by reacti ve oxygen species-medi ated autophagy is escap ed in CD44 variant-exp ressing cancer stem-like cells.	Cell Host. & Microbe.	12(6)	764-777	2012
Fujii, Y., Yoshihashi, K., Suzuki, H., Tsutsumi, S., Mutoh, H., Maeda, S., Aburatani, H., Hatakeya ma, M.	CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemness-associated reprogramming factors SALL4 and KLF5.	Proc. Natl. Acad. Sci. USA	109(50)	20584-2058 9	2012
Suzuki, H., Moayyedi, P.	Helicobacter pylori infection in functional dyspepsia.	Nat. Rev. Gastroenterol. Hepatol.	10(3)	168-74	2013
Hirata, K., <u>Suzuki, H.</u> , Matsuzaki, J., Masaoka, M., Saito, Y., Nishizawa, T., Iwasaki, E., Fukuhar a, S., Okada, S., Hibi, T.	Improvement of reflux symptom related quality of life after <i>Helicobac</i> ter pylori eradication th erapy.	J. Clin. Biochem. Nutri.	52(2)	172-178	2013
Matsuzaki, J., Suzuki, H., Okuda, S., Tanimoto, A., Asakura, K., Fukuha ra, S., Okada, S., Hirata, K., Mori, H., Masaoka, T., Higuchi, H., Hozawa, S., Kuribayashi, S., Tak ebayashi, T., Hibi, T.	Biliary findings assist in predicting enlargement of intraductal papillary mucinous neoplasms of the pancreas.	Clin. Gastroenterol. Hepatol.	11(5)	548-54	2013
Takahashi, T., Suzuki, H., Imai, T, Shibata, S., Tabuchi, Y., Tsuchimoto, K., Okano, H., Hibi, T.	Musashi-1 post-transcrip tionally enhances phosp hotyrosine-binding dom ain- containing m-Num b protein expression in regenerating gastric mucosa.	PLoS One	8(1)	e53540	2013
Mogami, S., <u>Suzuki, H.</u> , Tsugawa, H., Fukuhara, S., Hibi, T.	Impaired heme oxygena se-1 induction in the g astric antrum induces d isruption of the interstit ial cells of Cajal network in a rat model of st reptozotocin-induced diabetes.	Neuro- gastroenterol. Motil.	in press	in press	2013

Suzuki, H., Matsuzaki, J., Okada, S., Fukuhara, S., Hirata, K., Hibi, T.	Validation of the Gerd Q questionnaire for the management of gastro esophageal reflux disease in Japan.	United European Gastroenterology Journal	in press	in press	2013
Mizuno, S., Yamagishi, Y., Ebinuma, H., Nakamo to, N., Katahira, M., Sasa ki, A., Sakamoto, M., Suzuki, H., Kanai, T., Hibi, T.	Progressive liver failure induced by everolimus for renal cell carcino ma in a 58-year-old m ale hepatitis B virus carrier.	Clin. J. Gastroenterol.	6(2)	188-192	2013
Nishizawa, T., <u>Suzuki,</u> <u>H.</u>	The role of microRNA in gastric malignancy.	Int. J. Mol. Sci.	14(5)	9487-9496	2013
Nishizawa, T., <u>Suzuki,</u> <u>H.</u> , Takahashi, M., Suzuk i, M., Hibi, T.	Delay of second-line er adication therapy for <i>H. pylori</i> can increase eradication failure.	J. Gastroenterol. Hepatol.	in press	in press	2013
Asaoka, D., Nagahara, A., Matsuhisa, T., Takaha shi, S., Tokunaga, K., Ka wai, T., Suzuki, H., Suzuki, M., Nishizawa, T., Kurihara, N., Ito, M., Sasa ki, H., Omata, F., Mizun o, S., Torii, A., Ohkusa, T., Mine, T., Sakaki, N.	Trends of second-line e radication therapy for <i>Helicobacter pylori</i> in Japan: A Multicenter S tudy in the Tokyo Met ropolitan Area.	Helicobacter	in press	in press	2013
Miyoshi, J., Yajima, T., Shimamura, K., Matsuok a, K., Okamoto, S., Higu chi, H., Funakoshi, S., Ta kaishi, H., <u>Hibi, T</u> .	5-aminosalicylic acid m ediates expression of c yclooxygenase-2 and 15 -hydroxyprostaglandin d ehydrogenase to suppre ss colorectal tumorigenesis.	Anticancer. Res.	32(4)	1193-202	2012
Takaishi, H., Kanai, T., Nakazawa, A., Sugata, F., Nikai, A., Yoshizawa, S., Hamamoto, Y., Funak oshi, S., Yajima, T., Iwa o, Y., Takemura, M., Oz aki, S., <u>Hibi, T.</u>	Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype.	J. Gastroenterol.	47(9)	969-77	2012
Hosoe, N., Nakashita, M., Imaeda, H., Sujino, T., Bessho, R., Ichikawa, R., Inoue, N., Kanai, T., <u>Hibi, T.</u> , Ogata, H.	Comparison of patient acceptance of sodium p hosphate versus polyeth ylene glycol plus sodiu m picosulfate for colon cleansing in Japanese.	J. Gastroenterol. Hepatol.	27(10)	1617-22	2012

Mizukami, T., Kanai, T., Mikami, Y., Hayashi, A., Doi, T., Handa, T., Mat sumoto, A., Jun, L., Mats uoka, K., Sato, T., Hisam atsu, T., Hibi T.	CCR9+ macrophages ar e required for eradicati on of peritoneal bacteri al infections and preve ntion of polymicrobial sepsis.	Immunol. Lett.	147(1-2)	75-9	2012
Hisamatsu, T., Kanai, T., Mikami, Y., Yoneno, K., Matsuoka, K., Hibi, T.	Immune aspects of the pathogenesis of inflam matory bowel disease.	Pharmacol. Ther.	137(3)	283-97	2013
Takahashi, T., Suzuki, H., Imai, T., Shibata, S., Ta buchi, Y., Tsuchimoto, K., Okano, H., Hibi, T.	Musashi-1 post-transcrip tionally enhances phosp hotyrosine-binding dom ain-containing m-Numb protein expression in r egenerating gastric mucosa.	PLoS One.	8(1)	e53540	2013
Arai, T., Yuasa, S., Miya ta, H., Kawamura, A., M aekawa, Y., Ishikawa, S., Noma, S., Inoue, S., <u>Sato, Y.</u> , Kohsaka, S., Fuku da, K.	Incidence of periproced ural myocardial infarcti on and cardiac biomark er testing after percutan eous coronary interventi on in Japan: results from a multicenter registry.	Heart. Vessels.	Epub ahead of print	Epub ahead of print	2012
Numasawa, Y., Kohsaka, S., Miyata, H., Kawamur a, A., Noma, S., Suzuki, M., Nakagawa, S., Momi yama, Y., Sato, Y., Fuku da, K.	Safety of transradial ap proach for percutaneous coronary intervention in relation to body mas s index: a report from a Japanese multicenter registry.	Cardiovasc. Interv. Ther.	28(2)	148-56	2013
Kuwahara, E., Asakura, K., Nishiwaki, Y., Inoue, N., Watanabe, M., Hibi, T., <u>Takebayashi, T.</u>	Effects of family histor y on inflammatory bow el disease characteristic s in Japanese patients.	J. Gastroenterol.	47(9)	961-8	2012
Yamada, M., Nishiwaki, Y., Michikawa, T., <u>Take</u> bayashi, T.	Self-reported hearing lo ss in older adults is as sociated with future de cline in instrumental ac tivities of daily living but not in social partici pation.	J. Am. Geriatr. Soc.	60(7)	1304-9	2012
Inamasu, T., Sudo, K., K ato, S., Deguchi, H., Ichi kawa, M., Shimizu, T., Maeda, T., Fujimoto, S., Takebayashi, T., Saito, T.	Pandemic influenza vir us surveillance, Izu-Osh ima Island, Japan.	Emerg. Infect. Dis.	18(11)	1882-5	2012
Iwase, T., <u>Takebayashi,</u> <u>T.</u> , Tanimoto, K., Terashi ma, Y., Miyakawa, T., K obayashi, T., Tohse, N., Yamashita, T.	Sympathectomy attenuat es excitability of dorsal root ganglion neurons and pain behaviour in a lumbar radiculopathy model.	Bone Joint Res.	1(9)	198-204	2012

Michikawa, T., Nishiwak i, Y., Asakura, K., Hilleb rand, G., Miyamoto, K., Ono, M., Kinjo, Y., Akib a, S., <u>Takebayashi, T.</u>	Sunlight exposure may be a risk factor of hea ring impairment: a com munity-based study in Japanese older men and women.	J. Gerontol. A. Biol. Sci. Med. Sci.	68(1)	96-103	2013
Takebayashi, T., Yoshim oto, M., Ida, K., Tsuda, H., Terashima, Y., Yamas hita, T.	Minimum invasive post erior decompression for cervical spondylotic a myotrophy.	J. Orthop. Sci.	18(2)	205-7	2013
Mizutani, N., Kawato, H., Maeda, Y., <u>Takebayash</u> <u>i, T.</u> , Miyamoto, K., Hori uchi, T.	Multiple-type dynamic culture of highly orient ed fiber scaffold for ligament regeneration.	J. Artif. Organs.	16(1)	49-58	2013
Nishiwaki, Y., Michikaw a, T., <u>Takebayashi, T.</u> , Nitta, H., Iso, H., Inoue, M., Tsugane, S.; Japan P ublic Health Center-based Prospective Study Group.	Long-term exposure to particulate matter in rel ation to mortality and i neidence of cardiovascu lar disease: the JPHC Study.	J. Atheroscler. Thromb.	20(3)	296-309	2013
Takebayashi, T., Horii, T., Denno, H., Nakamach i, N., Otomo, K., Kitamu ra, S., Miyamoto, K., Horiuchi, T., Ohta, Y.	Human mesenchymal st em cells differentiate to epithelial cells when c ultured on thick collagen gel.	Biomed. Mater. Eng.	23(1-2)	143-53	2013
Michikawa, T., Nishiwak i, Y., Nakano, M., Iwasa wa, S., Yamada, M., Asa kura, K., Yoshioka, N., Kuwahara, E., <u>Takebayas hi, T.</u>	Higher Serum Dehydro epiandrosterone Sulfate Levels Are Protectivel y Associated With Dep ressive Symptoms in M en, But Not in Women: A Community-Based Cohort Study of Older Japanese.	Am. J. Geriatr. Psychiatry.	\$1064- 7481 (13)	00059-6	2013
Nakashima, H., Omae, K., Nomiyama, T., Yama no, Y., <u>Takebayashi, T.</u> , Sakurai, Y.	Beta-3-adrenergic recept or Trp64Arg polymorph ism: does it modulate t he relationship between exercise and percentag e of body fat in young adult Japanese males?	Environ. Health. Prev. Med.	Epub ahead of print	Epub ahead of print	2013
Kamitani, K., Michikawa, T., Iwasawa, S., Eto, N., Tanaka, T., <u>Takebay</u> ashi, T., Nishiwaki, Y.	Spinal Posture in the S agittal Plane Is Associa ted With Future Dependence in Activities of Daily Living: A Community-Based Cohort Study of Older Adults in Japan.	J. Gerontol. A. Biol. Sci. Med. Sci.	Epub ahead of print	Epub ahead of print	2013

Yoshimoto, M., Iwase, T., <u>Takebayashi, T.</u> , Ida, K., Yamashita, T.	Microendoscopic Discectomy for Far Lateral Lumbar Disc Herniation: Less Surgical Invasiveness and Minimum Two-Year Follow-UpResults.	J. Spinal. Disord. Tech.	Epub ahead of print	Epub ahead of print	2013
Hokari, R., Kurihara, C., Nagata, N., Aritake, K., Okada, Y., Watanabe, C., Komoto, S., Nakamura, M., Kawaguchi, A., Naga o, S., Urade, Y., Miura, S.	Increased expression of lipocalin-type-prostagla ndin D synthase in ulc erative colitis and exac erbating role in murine colitis.	Am. J. Physiol., Gastrointest. Liver Physiol.	302 (3)	G401-8	2011
Kishikawa, H., Nishida, J., Ichikawa, H., Kaida, S., Matsukubo, T., Miura, S., Morishita, T., Hibi, T.	Serum nitrate/nitrite co ncentration correlates w ith gastric juice nitrate/ nitrite: a possible mark er for mutagenesis of t he proximal stomach.	Digestion.	84 (1)	62-9	2011
Matsunaga, H., Hokari, R., Ueda, T., Kurihara, C., Hozumi, H., Higashiy ama, M., Okada, Y., Wat anabe, C., Komoto, S., N akamura, M., Kawaguchi, A., Nagao, S., Sekiyam a, A., Miura, S.	Physiological stress exa cerbates murine colitis by enhancing proinflam matory cytokine expres sion that is dependent on IL-18.	Am. J. Physiol. Gastrointest. Liver Physiol.	301 (3)	G555-64	2011
Miura, S., Sugano, K., Kinoshita, Y., Fock, K. M., Goh, K.L., Gibson, P.; Asian-Pacific Topic C onference organized by Ja panese Society of Gastroe nterology and Asian Pacific Association of Gastroenterology.	Diagnosis and treatment of functional gastroint estinal disorders in the Asia-Pacific region: a survey of current practices.	J. Gastroenterol. Hepatol.	26 Supp 3	12-11	2011
Kishikawa, H., Nishida, J., Ichikawa, H., Kaida, S., Takarabe, S., Matsuku bo, T., Miura, S., Moris hita T, Hibi T.	Fasting Gastric pH of Japanese Subjects Stratified by IgG Concentration Against Helicobacter pylori and Pepsinogen Status.	Helicobacter.	16(6)	427-33	2011
Miwa, H., Ghoshal, U.C., Fock, K.M., Gonlachanv it, S., Gwee, K.A., Ang, T.L., Chang, F.Y., Hong o, M., Hou, X., Kachinto rn, U., Ke, M., Lai, K. H., Lee, K.J., Lu, C.L., Mahadeva, S., Miura, S., Park, H., Rhee, P.L., Su gano, K., Vilaichone, R. K., Wong, B.C., Bak, Y. T.	Asian Consensus Repor t on Functional Dyspepsia.	J. Gastroenterol. Hepatol.	27 (4)	626-41	2012

Miura, S., Hokari, R.	Seeking an optimal era dication therapy for Helicobacter pylori infection.	J. Gastroenterol. Hepatol.	27 (1)	7-9	2012
Higashiyama, M., Hokari, R., Hozumi, H., Kurihar a, C., Ueda, T., Watanab e, C., Tomita, K., Nakam ura, M., Komoto, S., Oka da, Y., Kawaguchi, A., Nagao, S., Suematsu, M., Goda, N., Miura, S.	HIF-1 in T cells ameli orated dextran sodium sulfate-induced murine colitis.	J. Leukoc. Biol.	91(6)	901-909	2012
Miwa, H., Ghoshal, U.C., Gonlachanvit, S., Gwee, K.A., Ang, T.L., Chang, F.Y., Fock, K.M., Hong o, M., Hou, X., Kachinto rn, U., Ke, M., Lai, K. H., Lee, K.J., Lu, C.L., Mahadeva, S., Miura, S., Park, H., Rhee, P.L., Su gano, K., Vilaichone, R. K., Wong, B.C., Bak, Y. T.	Asian Consensus Report on Functional Dyspepsia.	J. Neuro- gastroenterol. Motil.	18 (2)	150-68	2012
Miura, S., Hokari, R., Ts uzuki, Y.	Mucosal immunity in g ut and lymphoid cell tr afficking.	Annals of Vascular Diseases.	5(1)	275-281	2012
Nakamizo, H., Suzuki, H., Miura, S., Mogami, S., Kishikawa, H., Yoshid a, H., Matsui, H., Hibi, T.	Transmural pressure loa ding enhances gastric mucosal cell proliferati on.	Dig. Dis. Sci.	57 (10)	2545-2554	2012
Tsujimoto, H., Ogata, S., Yaguchi, Y., Kumano, I., Takahata, Ra., Ono, S., Yamamoto, J., Nagao, S., Miura, S., Hase, K.	Predictive value of the pathological extent of tumor invasion in endo scopic resection margin s positive for residual t umor cells in surgically resected specimens of early gastric cancer.	Exp. Ther. Med.	4(3)	507-513	2012
Higashiyama, M., Hokari, R., Kurihara, C., Ueda, T., Watanabe, C., Tomita, K., Komoto, S., Okada, Y., Kawaguchi, A., Naga o, S., Miura S.	Indomethacin-induced s mall intestinal injury is ameliorated by cilosta zol, a specific PDE-3 i nhibitor.	Scand. J. Gastroenterol.	8-9 (47)	993-1002	2012
Nakashita, M., Suzuki, H., Miura, S., Taki, T., Uehara, K., Mizushima, T., Nagata, H., Hibi, T.	Attenuation of acetic a cid-induced gastric ulce r formation in rats by glucosylceramide synthase inhibitors.	Dig. Dis. Sci.	58	354-362	2013

	<b>T</b>		T	T	Ι
Sato, S., Hokari, R., Kuri hara, C., Sato, H., Narim atsu, K., Hozumi, H., Ue da, T., Higashiyama, M., Okada, Y., Watanabe, C., Komoto, S., Tomita, K., Kawaguchi, A., Nagao, S., Miura, S.	Dietary lipids and swee teners regulate glucago n-like peptide-2 secretion.	Am. J. Physiol. Gastrointest. Liver. Physiol.	304(8)	G708-714	2013
Hozumi, H., Hokari, R., Kurihara, C., Narimatsu, K., Sato, H., Sato, S., Ue da, T., Higashiyama, M., Okada, Y., Watanabe, C., Komoto, S., Tomita, K., Kawaguchi, A., Nagao, S., Miura, S.	Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha ex pression in colonic mu cosa of patients with u lcerative colitis.	Int. J. Colorectal. Dis.		Epub ahead of print	2013
Hozumi, H., Hokari, R., Kurihara, C., Narimatsu, K., Sato, H., Sato, S., Ue da, T., Higashiyama, M., Okada, Y., Watanabe, C., Komoto, S., Tomita, K., Kawaguchi, A., Nagao, S., Miura, S.	Involvement of autotaxi n/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration.	Lab. Invest.		Epub ahead of print	2013
穂苅量太、 <u>三浦総一郎</u> .	III 最近の話題 消化管の恒 常性維持と病態解明、1。消化・吸収機能からのアプローチ、特集:小腸疾患:診断と治療の進歩	日本内科学会雑誌	100	126-132	2011
佐藤伸悟、穂苅量太、 <u>三</u> <b>浦総一郎</b> .	小腸のプログルカゴン由 来ホルモン分泌におけ る各種脂肪酸摂取の影 響	消化と吸収	33	246-250	2011
三浦総一郎、高本俊介、 渡辺知佳子、穂苅量太、 川口 淳	下部消化管疾患の治療 ガイドラインと高齢者へ の適応	日本高齢消化器病 学会誌	13	7-12	2011
安武優一、 <u>三浦総一郎</u> .	ローマ基準の意義とそ の概要	Modern Physician	31	289-91	2011
佐藤伸悟、 <u>三浦総一郎</u> 。	Glucagon-like peptide 2 (GLP-2)と小腸の消化・ 吸収	日本消化器病学会 雑誌	108	564-74	2011
三浦総一郎.	慢性胃炎と機能性ディスペプシアの治療戦略― 両疾患の相違点を踏まえてー	Physcians' Therapy Manual (PTM) 最新の疾 患別治療マニュア	3 (1)	1-2	2011
渡辺知佳子、 <u>三浦総一郎</u> .	アミノ酸、ペプチド輸送 体、消化管の輸送体	G.I. Research	19	418-425	2011

三浦総一郎、高本俊介、 渡辺知佳子、穂苅量太	高齢者潰瘍性大腸炎の 内科治療 潰瘍性大腸 炎診療の進展II内科治 療	日本大腸肛門会誌	64	825-28	2011
三浦総一郎	蛋白漏出性胃腸症	2012今日の治療 指針		438	2012
三浦総一郎、岡田義清、 上田俊秀、八月朔日秀 明、穂苅量太	Microscopic colitisの病態の解明にむけて一疾患モデル確立の試み	大腸疾患NOW20 12		58-62	2012
高本俊介、 <u>三浦総一郎</u>	高齢者の便通異常―憩 室症や虚血性大腸炎と の関連も含め	medicina (メディチ ーナ)	49	286-289	2012
八月朔日秀明、 <u>三浦総一</u> <u>郎</u>	炎症性腸疾患の免疫学 的要因 リンパ球ホーミ ング、接着分子の関与	日本臨牀	70 (増 刊号)	101-105	2012
八月朔日秀明、穂苅量 太、佐藤伸悟、上田俊秀、 東山正明、岡田義清、栗 原千枝、渡辺知佳子、高 本俊介、中村光康、冨田 謙吾、川口 淳、永尾重 昭、三浦総一郎	腸管粘膜の微小血管に おけるautotaxin/lysopho spholipase Dの発現とリ ンパ球マイグレーション に伴なう腸管障害との関 連	消化器と免疫	48	116-119	2012
永尾重昭、清水基規、高 城健、丸田紘史、成松和 幸、佐藤宏和、川口淳、 三浦総一郎	赤外線内視鏡	Frontiers in Gastroenterology	17 (2)	147-152	2012
成松和幸、 <u>三浦総一郎</u>	吸収不良症候群	ビジュアル栄養療 法		12-18	2012
穂苅量太、 <u>三浦総一郎</u>	蛋白漏出性胃腸症、吸 収不良症候群	日本医師会雑誌	141(特別号)	188-190	2012
三浦総一郎	慢性下痢、成人	新臨牀栄養学第2 版		520-528	2012
Kamiya, T., <u>Joh, T.</u> , Soll ano, JD., Zhu, Q., Kachi ntorn, U., Aziz Rani, A., Hahm, KB., Takahashi, S., Kinoshita, Y., Matsum oto, T., Naito, Y., Takeu chi, K., Arakawa, T., Ter ano, A.	Consensus of the prese nt and prosoects on en doscopic diagnosis and treatment in East Asian countries.	Diagn. Ther. Endosc.	in press	in press	2012
Quach, DT., Le, HM., N guyen, OT., Nguyen, TS., <u>Uemura, N</u> .	The severity of endosc opic gastric atrophy co uld help to predict Ope rative Link on Gastritis Assessment gastritis stage.	J. Gastroenterol. Hepatol.	26	281-5	2011

Nagata, N., Kobayakawa, M., Shimbo, T., Hoshim oto, K., Yada, T., Gotod a, T., Akiyama, J., Oka, S., <u>Uemura, N.</u>	Diagnostic value of ant igenemia assay for cyto megalovirus gastrointest inal disease in immuno compromised patients.	World J. Gastroenterol.	17	1185-91	2011
Kinoshita, Y., Ashida, K., Hongo, M.; Japan Rabe prazole Study Group for NERD.	Randomised clinical tri al: a multicentre, doubl e-blind, placebo-controll ed study on the efficac y and safety of rabepra zole 5 mg or 10 mg o nce daily in patients w ith non-erosive reflux disease.	Aliment. Pharmacol. Ther.	33(2)	213-24	2011
Hijikata, Y., Ogasawara, N., Sasaki, M., Mizuno, M., Masui, R., Kondo, Y., Izawa, S., Ito, Y., No da, H., <u>Kasugai, K.</u>	Endoscopic Submucosal Dissection with Sheath -Assisted Counter Tract ion Using a Novel She ath for Early Gastric Cancers.	Hepato- gastroenterology	59	353-356	2012
Sasaki, M., Imaeda, K., Okayama, N., Mizuno, T., Kataoka, H., Kamiya, T., Kubota, E., Ogasawa ra, N., Funaki, Y., Mizun o, M., Iida, A., Goto, C., Koikeda, S., Kasugai, K., Joh, T.	Effects of transglucosid ase on diabetes, cardio vascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	Diabetes. Obes. Metab.	14(4)	379-82	2012
Kawamura, Y., Ogasawar a, N., Yamamoto, S., Sas aki, M., Kawamura, N., I zawa, S., Kobayashi, Y., Kamei, S., Miyachi, M., Kasugai, K.	Gossypiboma mimickin g gastrointestinal strom al tumor causing intestinal obstruction: a case report.	Case. Rep. Gastroenterol.	6(2)	23-27	2012
Iida, A., Kaneko, H., Ko nagaya, T., Funaki, Y., T okudome, K., Izawa, S., Tamura, Y., Mizuno, M., Ogasawara, N., Sasaki, M., <u>Kasugai, K.</u>	Inhibition of gastric per ception of mild distenti on by omeprazole in v olunteers.	World. J. Gastroenterol.	18(39)	5576-80	2012
Tokudome, K., Funaki, Y., Sasaki, M., Izawa, S., Tamura, Y., zida, A., O gasawara, N., Konagaya, T., Tokura, Y., <u>Kasugai, K.</u>	Efficacy of endoluminal gastroplication in Japa nese patients with prot on pump inhibitor-resist ant, non-erosive esophagitis.	World. J. Gastroenterol.	18(41)	5940-7	2012
佐々木誠人、水野真理、 岡庭紀子、川村百合加、 高田真由子、 <b>春日井邦</b> <u>夫</u> .	【炎症性腸疾患-病因解明と診断・治療の最新知見-】炎症性腸疾患の検査・診断 高齢者炎症性腸疾患の臨床的特徴	日本臨牀	70(1)	266-269	2012

篠原孝幸、岩堀祐之,福 井真二,春日井邦夫	ヘシアンフィルタを用い た内視鏡画像からのポリ ープ自動検出	電子情報通信学会 医用画像研究技術 報告	111(389)	305-10	2012
足立和規、田中創始,小 林佑次,林伸彦,石井紀 光,金澤太茂,佐々木誠 人,中尾春壽,春日井邦 夫,米田政志	若年者に発症した石灰 乳胆汁による閉塞性黄 疸に対し、EPBDが奏功 した1例	Gastroenterological . Endoscopy.	54(3)	466-473	2012
佐々木誠人、伊藤義紹, 舟木康,小笠原尚高,水 野真理,飯田章人,河村 直彦,徳留健太郎,土方 康孝,井澤晋也,増井竜 太,近藤好博,田村泰弘, 野田久嗣,岡庭紀子,誠 野田久嗣,岡庭紀子,誠 司,川村百合加,高田真 由美,新村哲也,小松原 利典,春日井邦夫	ジクロフェナクによる小 腸粘膜傷害に対する予 防	Ulcer Research.	39(2)	168-171	2012
春日井邦夫、舟木康、飯 田章人	【機能性消化管障害の 診断と治療】NERDの 病態(解説/特集)	Medical Science Digest	38(12)	523-525	2012
木下芳一、三輪洋人、 <u>春</u> 日井邦夫.	逆流性食道炎初期治療 に対するエソメプラゾー ルの有効性の検討 ー オメプラゾールを対照と した無作為化二重盲検 比較試験一	日消誌	110(2)	32-40	2013
Ando, T., Mizuno, S., Ish ida, T., Kondo, Y., Miki, I., Yoshida, M., Azuma, T., Ishikawa, T., Takagi, T., Yagi, N., Kokura, S., Naito, Y., Yoshikawa, T., Asakawa, A., Inui, A.	Plasma ghrelin isoforms and gastric ghrelin O-acyltransferase expressi on are influenced by <i>H elicobacter pylori</i> status.	Nutrition.	28	967-972	2012
Inoue, K., Wakabayashi, N., Fukumoto, K., Yamad a, S., Bito, N., Yoshida, N., Katada, K., Uchiyam a, K., Ishikawa, T., Hand a, O., Takagi, T., Konish i, H., Yagi, N., Kokura, S., Kishimoto, M., Yanag isawa, A., Naito, Y.	Toxic Megacolon Asso ciated with Cytomegalo virus Infection in a Pat ient with Steroid-naive Ulcerative Colitis.	Intern. Med.	51	2739-2743	2012
Ogawa, K., Omatsu, T., Matsumoto, C., Tsuchiya, N., Yamamoto, M., <u>Nait</u> o, <u>Y.</u> , Yoshikawa, T.	Protective effect of the Japanese traditional m edicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential bio marker of this effect.	BMC Complement. Altern. Med.	12	118	2012

Senmaru, T., Fukui, M., Tanaka, M., Kuroda, M., Yamazaki, M., Oda, Y., Naito, Y., Hasegawa, G., Toda, H., Yoshikawa, T., Nakamura, N.	Atrophic gastritis is ass ociated with coronary a rtery disease.	J. Clin. Biochem. Nutr.	51	39-41	2012
Tanaka, M., Fukui, M., Kuroda, M., Yamazaki, M., Hasegawa, G., Oda, Y., Naito, Y., Toda, H., Yoshikawa, T., Nakamur a, N.	Pepsinogen I/II ratio is related to glucose, tria cylglycerol, and uric ac id levels.	Nutrition.	28	418-421	2012
Ando, T., Ishikawa, T., T akagi, T., Imamoto, E., K ishimoto, E., Okajima, A., Uchiyama, K., Handa, O., Yagi, N., Kokura, S., Naito, Y., Mizuno, S., Asakawa, A., Inui, A., Yoshikawa, T.	Impact of <i>Helicobacter pylori</i> Eradication on Circulating Adiponectin in Humans.	Helicobacter.	18	158-164	2013
Nishizawa, T., Suzuki, H., Maekawa, T., Harada, N., Toyokawa, T., Kuwa i, T., Ohara, M., Suzuki, T., Kawanishi, M., Nog uchi, K., Yoshio, T., Kat sushima, S., Tsuruta, H., Masuda, E., Tanaka, M., Katayama, S., Kawamura, N., Hibi, T., Takahashi, M.	Dual therapy as third-line regimen for <i>H. pylo ri</i> eradication and prediction by urea breath test.	World J. Gastroenterol.	18(21)	2735-38	2012
Suzuki, H., <u>Nishizawa,</u> <u>T.</u> , Tsugawa, H., et al.	Molecular approaches a nd modern clinical strat egies for the managem ent of <i>H. pylori</i> infecti on in Japan.	Keio J. Med.	61(4)	109-19	2012
Nishizawa, T., Suzuki, H., Suzuki, M., Takahash i, M., Hibi, T.	Proton pump inhibitor amoxicillin clarithromy cin versus proton pump inhibitor amoxicillin metronidazole as first-li ne <i>Helicobacter pylori</i> eradication therapy.	J. Clin. Biochem. Nutr.	51(2)	114-6	2012
Suzuki, H., <u>Nishizawa,</u> <u>T.</u> , Tsugawa, H., et al.	Roles of oxidative stres s in stomach disorders.	J Clin Biochem Nutr.	50(1)	35-9	2012
Matsuzaki, J., Suzuki, H., Nishizawa, T., et al.	Efficacy of sitafloxacin- based rescue therapy fo r <i>Helicobacter pylori</i> af ter failures of first- and second-line therapies.	Antimicrob. Agents. Chemother.	56(3)	1643-5	2012

Iwasaki, E., Suzuki, H., Masaoka, T., <u>Nishizawa,</u> <u>T.</u> , et al.	Enhanced Gastric Ghrel in Production and Secr etion in Rats with Gast ric Outlet Obstruction.	Dig. Dis. Sci.	57(4)	858-64	2012
Nishizawa, T., Suzuki, H., Takahashi, M., Kanek o, H., Suzuki, M., Hibi, T.	Effect of ursodeoxychol ic acid and endoscopic sphincterotomy in lon g-term stenting for common bile duct stones.	J. Gastroenterol. Hepatol.	28(1)	63-7	2013
Hirata, K., Suzuki, H., M atsuzaki, J., Masaoka, T., Saito, Y., Nishizawa, T., et al.	Improvement of reflux symptom related quality of life after <i>H. pylori</i> eradicationtherapy.	J. Clin. Biochem. Nutr.	52(2)	172-8	2013
<b>西澤俊宏</b> , 鈴木秀和.	H. pylori 除菌治療によって何が変わるのか? 分子生物学からみた変 化	胃と腸	47(11)	1678-83	2013
高橋正彦、関佐知子、作野隆、木下聡、岩畔慶太、西澤俊宏、藤山洋一、水森美佐、金子博、海老沼浩利、日比紀文.	肝硬変患者における呼 気ガス分析計および体 成分分析計を用いた安 静時、基礎エネルギー 消費量の測定	消化と吸収	34(3)	242-246	2012
<b>西澤俊宏</b> ,鈴木秀和,高 橋正彦.	大腸癌スクリーニング法 の理想と限界:大腸内視 鏡熟練度による病変検 出率への影響	消化器内科	54(4)	435-437	2012
永原章仁, 水野滋章, 松 久威史, 德永健吾, 伊藤 慎芳, 鈴木雅之, 浅岡大 介, 鈴木秀和, <b>西澤俊宏</b> , 他.	H. pylori 除菌後胃癌 について・除菌後10年 以上経過後に診断され た胃癌例の検討-東京都 内多施設共同調査-	日本ヘリコバクター学会誌	14(1)	2-6	2012
西澤俊宏,鈴木秀和,高 橋正彦,他.	H. pylori 除菌不成功 によるアモキシリン耐性 化とPBP1遺伝子変異	日本ヘリコバクター学会誌	13(2)	47-49	2012
<b>西澤俊宏</b> , 西澤優子.	過敏性腸症候群の診か た:薬物療法	治療	94(3)	369 -73	2012
鈴木秀和、 <u>西澤俊宏</u> 、日 比紀文.	H. pylori と胃癌の基礎 と臨床, H. pylori 病原 機序、薬剤耐性機構	消化器内科	54(3)	290-295	2012
鈴木秀和, <u>西澤俊宏</u> , 日 比紀文.	機能性ディスペプシア・ 代表的疾患の診療の現 況と将来展望	日本内科学会雑誌	102(1)	63-69	2013
西澤俊宏, 木下聡, 岩畔 慶太, 作野隆, 藤山洋一, 菊池美穂, 金子博, 鈴木 秀和, 高橋正彦.	bevacizumabを併用した XELOXおよびIRIS療法 により病勢がコントロー ルできた著明な肝転移 を伴う大腸癌の一例	癌と化学療法	in press	in press	in press

Hosoda, H., Kangawa, K.	Standard sample collect ions for blood ghrelin measurements.	Methods. Enzymol.	514	113-26	2012
Kaiya, H., <u>Hosoda, H.</u> , Kangawa, K., Miyazato, M.	Determination of nonm ammalian ghrelin.	Methods. Enzymol.	514	75-87	2012
Kojima, M., <u>Hosoda, H.</u> , Kangawa, K.	Purification of rat and human ghrelins.	Methods. Enzymol.	514	45-61	2012
Mao, Y., Tokudome, T., Otani, K., Kishimoto, I., Nakanishi, M., Hosoda, H., Miyazato, M., Kanga wa, K.	Ghrelin prevents incide nce of malignant arrhyt hmia after acute myoca rdial infarction through vagal afferent nerves.	Endocrinology.	153(7)	3426-34	2012
Hamada, N., Nishi, Y., T ajiri, Y., Setoyama, K., K amimura, R., Miyahara, K., Nuruki, N., <u>Hosoda, H.</u> , Kangawa, K., Kojim a, M., Mifune, H.	Disrupted regulation of ghrelin production und er antihypertensive treat ment in spontaneously hypertensive rats.	Circ. J.	76(6)	1423-9	2012
Suzuki, K., Murata, M., Y asuda, R., Tsuruta, H., <u>To motsugu, N.</u> , Abe, T., Iwa naga, S., Akaishi, M., Fuk uda, K.	Effect of lesional differ ences in prolapsed leafl ets on clinical outcome s in patients with mitra l valve prolapse.	Am. J. Cardiovasc. Dis.	2(3)	152-9	2012

IV. 研究成果の刊行物・別刷

### Roles of oxidative stress in stomach disorders

Hidekazu Suzuki,1,\* Toshihiro Nishizawa,1,2 Hitoshi Tsugawa,1 Sachiko Mogami1 and Toshifumi Hibi1

<sup>1</sup>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine,

(Received 20 September, 2011; Accepted 29 September, 2011; Published online 9 December, 2011)

The stomach is a sensitive digestive organ that is susceptible and exposed to exogenous pathogens from the diet. In response to such pathogens, the stomach induces oxidative stress, which might be related to the development of gastric organic disorders such as gastritis, gastric ulcers, and gastric cancer, as well as functional disorders such as functional dyspepsia. In particular, the bacterium Helicobacter pylori plays a major role in eliciting and confronting oxidative stress in the stomach. The present paper summarizes the pathogenesis of oxidative stress in the stomach during the development of various stomach diseases.

Key Words: gastric mucosa, oxidative stress, Helicobacter pylori

### Oxidative Stress in the Process of Gastric Mucosal Injury

Physiological responses to stressors include increased activity of the hypothalamic-pituitary-adrenal axis as well as changes in gastrointestinal tissue. According to Selye's formulation of the general adaptation syndrome, an increase in adrenocortical activity is related to an increase in the incidence of gastric ulceration. The main candidate for the cause of stress ulcers is oxidative stress. There is some evidence that psychological stress, in addition to physical stress such as surgical intervention and microbial infection including Helicobacter pylori (H. pylori),(1) leads to oxidative stress in the stomach. Oxidative stress, which is a state of elevated levels of reactive oxygen species (ROS), causes a variety of conditions that stimulate either additional ROS production or a decline in antioxidant defenses. Oxidative stress is not only involved in the pathogenesis of gastric inflammation, ulcerogenesis, and carcinogenesis in H. pylori infection, but also in that of lifestyle-related diseases including atherosclerosis, hypertension, diabetes mellitus, ischemic heart diseases, and malignancies. (2) Several phenotypes of gastrointestinal diseases, such as peptic ulcer disease and gastroparesis, are known to be related to antioxidant property dysfunction.

Ethanol. The effects of ethanol on gastric mucosa are complicated and multifaceted. They may be associated with a disturbance in the balance between gastric mucosal protective and aggressive factors. Gastric mucosa is exposed to gastric acid, pepsin, and stimulants among others, while gastroprotective factors maintain the integrity of the gastric mucous layer, microcirculatory system, HCO<sub>3</sub>-, prostaglandins (PGs), epidermal growth factor synthesis, and epithelial cell restitution. Ethanol injures the vascular endothelial cells of the gastric mucosa and induces microcirculatory disturbance and hypoxia, linking to the overproduction of oxygen

Pan et al.(3) report the role of mitochondrial energy charge in the pathogenesis of ethanol-induced gastric mucosal injury. The gastric mucosal lesion index is correlated with the thiobarbituric acid (TBA)-reactive substance (TBARS) content in gastric mucosa. As the concentration of ethanol increases and the exposure time to ethanol is extended, the TBARS content in gastric mucosa and the extent of gastric mucosal damage increase. The ultrastructural pathological changes in mitochondria are positively related to ethanol concentration and exposure time. The expressions of mitochondrial DNA ATPase subunits 6 and 8 mRNA decline with increasing TBARS content in gastric mucosa produced as a result of ethanol gavage. As mentioned above, ethanol-induced gastric mucosal injury is related to oxidative stress, which disturbs the energy metabolism of mitochondria and plays a critical role in the pathogenesis of ethanol-induced gastric mucosal injury.

Ischemia/reperfusion injury. Ischemia/reperfusion damages the gastric mucosa by inducing oxidative stress. Specifically, ROS such as superoxide (O2-) and hydrogen peroxide (H2O2) induce inflammatory responses and tissue damage by fragmenting cellular DNA. In the gut, ROS can also be generated by non-steroidal antiinflammatory drugs (NSAIDs), cold stress, ethanol, and H. pylori infection. NADPH oxidase found in phagocytic cells, vascular smooth muscle cells, endothelial cells, fibroblasts, and adipocytes convert oxygen into superoxide anions. Nakagiri et al. (4) recently reported that NADPH oxidase activity is elevated in ischemia and ischemia/reperfusion and is involved in the resultant gastric mucosal damage. This increased NADPH oxidase activity may also upregulate cyclooxygenase-2.

Peskar et al. (5) report that during ischemia/reperfusion, inhibitors of the cyclooxygenase and lipoxygenase pathways increase gastric mucosal damage in a dose-dependent manner. The synergism observed as a result of the combination of cyclooxygenase and lipoxygenase inhibitors suggests that both pathways are important in gastric mucosal defense during ischemia/reperfusion. PGE2 theoretically antagonizes the effects of cyclooxygenase and lipoxygenase inhibitors. Similarly, lipoxin A4, a lipoxygenasederived product of arachidonate metabolism, also antagonizes the effects of cyclooxygenase and lipoxygenase inhibitors; moreover, it could replace PGE2 for the prevention of gastric mucosal damage caused by cyclooxygenase inhibitors during ischemia/ reperfusion.

Portal hypertensive gastropathy. Portal hypertensive gastropathy (PHG) is a common complication of liver cirrhosis and is associated with impaired gastric mucosal healing. PHG may be related to increased ROS and lipid peroxide (LPO) production. Kinjo et al. (4) report increased levels of LPO and nitrotyrosine, an indicator of nitration of tyrosine residues due to peroxynitrite, in the gastric mucosa of portal hypertensive rats; in addition, they report impaired ERK1/2 phosphorylation related to increased nitration by peroxynitrite. The gastroprotective, anti-inflammatory agent rebamipide prevents free radical production by scavenging

He received "SFRR Japan Award of Scientific Excellent" in 2011 in recognition of his outstanding work.

doi: 10.3164/jcbn.11-115SR @2012 JCBN

J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 35-39

<sup>35</sup> Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
<sup>2</sup>Division of Gastroenterology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan

<sup>\*</sup>To whom correspondence should be addressed. E-mail: hsuzuki@a6.keio.jp

hydroxyl radicals.<sup>(5,6)</sup> Rebamipide decreases LPO and nitrotyrosine levels, normalizes ERK1/2 phosphorylation, and improves the ulcer index; this suggests that defects in the mitogen-activated protein kinase (MAPK) pathway are involved in the increased susceptibility to gastric mucosal injury observed in portal hypertensive gastropathy, indicating a potential role of rebamipide for treatment.

**NSAIDs and aspirin.** In addition to inhibiting cyclooxygenase and decreasing prostaglandin production, NSAIDs induce mucosal damage *via* ROS produced by recruited leukocytes. ROS-mediated mitochondrial damage as well as lipid, protein, and DNA oxidation lead to apoptosis and mucosal injury. Proton pump inhibitor (PPI) therapy is thought to primarily protect gastric mucosa by inhibiting gastric acid secretion. Nevertheless, Maity *et al.*<sup>(7)</sup> recently demonstrated that a PPI, lansoprazole, also inhibits NSAID-induced gastropathy by inhibiting mitochondrial and Fas-mediated apoptosis pathways. Lansoprazole's anti-apoptotic activity appears to be mediated by preventing NSAID-induced reductions in anti-apoptotic genes (e.g., Bcl and Bcl-2) while inhibiting increases in Fas and Fas ligand as well as pro-apoptotic genes (e.g., Bax and Bak).

On the other hand, aspirin increases the permeability of cultured gastric epithelial cell monolayers. The disruption in barrier integrity is mediated by p38 MAPK and involves the downregulation of claudin-7, a protein component of tight junctions. (8) This differs from the effects of other NSAIDs (i.e., non-aspirin NSAIDs), which increase epithelial permeability coupled to cyclooxygenase-1 inhibition; this increase can be restored by PGE2 administration.

**Heat shock proteins.** Heat shock proteins, especially HSP70, provide cellular protection against stressor-induced tissue damage by refolding or degrading denatured proteins produced as a result of these stressors. Otaka et al. (9) recently used affinity chromatography to identify cytoskeletal myosin and actin as the first molecules bound by HSP70 after gastric mucosal injury in rats. Transcriptional upregulation of HSPs occurs via the binding of the transcription factor, heat shock factor 1 (HSF1), to heat shock element, which is located upstream of the HSP genes. In HSF1 null and HSP70-expressing transgenic mice, HSPs protect against irritant (e.g., ethanol or NSAIDs)-induced gastric lesions; moreover, geranylgeranylacetone (GGA), a gastroprotective agent, induces HSPs. Furthermore, HSP70 protects the gastric mucosa by inhibiting apoptosis, proinflammatory cytokines, and cell adhesion molecules involved in leukocyte infiltration. After induction by GGA, HSPs exhibit protective effects in mouse models of inflammatory bowel disease as well as in NSAIDinduced lesions of the small intestine. Therefore, HSP inducers such as GGA may have therapeutic benefits in numerous diseases.

#### **Enlarged Fold Gastritis and Oxidative Stress**

H. pylori eradication therapy increases Runt domain transcription factor 3 (RUNX3) expression in glandular epithelial cells in enlarged-fold gastritis. Recently, we reported that RUNX3 is expressed in gastric epithelial cells and that H. pylori eradication significantly increases RUNX3 expression in the glandular epithelium of the corpus; however, no changes were observed in the antrum. (10) The mucosal chemiluminescence value, a marker of oxidative stress, is 4-fold higher in the corpus than in the antrum. H. pylori eradication significantly decreases the mucosal chemiluminescence values in both portions of the stomach to nearly undetectable levels. We conclude that the glandular epithelium is exposed to high levels of carcinogenic oxidative stress and expresses low levels of the tumor-suppressing molecule, RUNX3; however, RUNX3 expression was restored after eradication, suggesting a high risk of carcinogenesis associated with H. pylori-induced enlarged-fold gastritis of the corpus. (10)

#### Oxidative Stress during H. pylori Infection

Antioxidant ability of *H. pylori* to establish chronic infection. *H. pylori* infection induces a strong inflammatory host response, leading to the generation of a number of ROS and reactive nitrogen species (RNS), which are mediated by neutrophils and macrophages. The generation of ROS and/or RNS is an important host immune response against persistent pathogens. Therefore, *H. pylori* must combat oxidative stress generated by the host immune response using an antioxidant protein in order to establish long-term colonization. ROS detoxification are of particular interest in understanding the *H. pylori*-associated pathogenesis. It is well known that *H. pylori* has a variety of enzymes acting as antioxidant systems to combat the toxic effects of ROS including catalase (KatA), iron-cofactored superoxide dismutase (SodB), and alkyl hydroperoxide reductase (AhpC). (13,14)

Superoxide dismutase (SOD) catalyzes the conversion of superoxide anions to hydrogen peroxide, which is degraded to oxygen and water by catalase. (13,15) SOD is a metalloenzyme; 3 structurally different forms have been identified depending on the metal cofactor. In general, organisms encode different sets of SOD enzymes. For example, Escherichia coli has 3 SODs: Fe-SOD (SodB) and Mn-SOD (SodA) in the cytoplasm and Cu/Zn-SOD in the periplasm. (16) On the other hand, H. pylori produces only a single SodB encoded by the sodB gene. (17,18) It was recently reported that sodB deletion in H. pylori causes the bacterium to lose its capacity for gastric mucosal colonization in mice. (19) This indicates that SodB is an important determinant of the host colonization capability of H. pylori. The regulation of sodB mRNA expression is also important for ROS detoxification. The mRNA expression of sodB in H. pylori is directly regulated by ferric uptake regulator (Fur) protein. (20) Fur functions as a global transcriptional regulator in *H. pylori*. (21-24) It is reported that Fur binds to ferrous iron (Fe<sup>2+</sup>) and that the genes for iron uptake are suppressed by the iron-binding form of Fur. (25,26) On the other hand, sodB expression is suppressed by the iron-free form of Fur (apo-Fur). (20) Apo-Fur binds to a specific consensus sequence called Fur-Box located on the *sodB* promoter, blocking the binding of RNA polymerase. (20,27,28) It was recently reported that nucleic-acid mutations in Fur-Box and/or amino-acid mutations in Fur decrease the affinity of apo-Fur for Fur-Box in H. pylori, halting the suppression of sodB mRNA expression. (29-31) In particular, stopping the suppression of sodB mRNA expression in H. pylori by amino-acid mutations in Fur (i.e., C78Y and P114S) determines the development of metronidazole (Mtz) resistance. (31) This is because, when Mtz enters cells, its antimicrobial toxicity is dependent on the reduction of its nitro group to nitro anion radicals and the generation of superoxide. (32,33)

The SodB of *H. pylori* shares 53% sequence identity with the corresponding protein from *E. coli*. Interestingly, *H. pylori* SodB is significantly different from other Fe-SODs; its most distinguishing characteristic is its extended C-terminal tail,<sup>(34)</sup> although the role of this tail remains unclear. The structure of SodB has been clarified; it is now known to exist as a dimer composed of 2 identical subunits.<sup>(34)</sup> Furthermore, it is identified as having 4 ferrous ion (Fe<sup>2+</sup>)-coordinating residues (i.e., an iron-binding domain; His 26, His 73, His 160, and Asp 156) (Fig. 1). In fact, SodB needs to recruit ferrous ion (Fe<sup>2+</sup>) to express its activity.<sup>(15,34)</sup> It is expected that SodB activity might be suppressed by preventing the uptake of iron ion (Fe<sup>2+</sup> and/or Fe<sup>3+</sup>).

Generation of oxidative stress as a virulence factor in *H. pylori*-infected hosts. ROS released from activated neutrophils are also potential virulence factors involved in *H. pylori*-infected host cells. In *H. pylori*-infected host cells, hypochlorous anions (OCl<sup>-</sup>) are generated from H<sub>2</sub>O<sub>2</sub> in the presence of Cl<sup>-</sup>. The hypochlorous anions subsequently react with ammonia (NH<sub>3</sub>), which is derived from urea by urease produced by *H. pylori*,

36 doi: 10.3164/jcbn.11-115SR ©2012 JCBN




Fig. 1. Homology modeling of *Helicobacter pylori* SodB. Four amino acids (His 26, His 73, His 160, and Asp 156) of SodB are ferrous ion (Fe<sup>2+</sup>)-coordinating residues (i.e., an iron-binding domain).

ultimately yielding monochloramine (NH<sub>2</sub>Cl). NH<sub>2</sub>Cl induces mucosal cytotoxicity due to its lipophilic properties and freely penetrates biological membranes to oxidize intracellular components. (35-37)

In addition, it is well known that *H. pylori* produces a γ-glutamyltranspeptidase (EC 2.3.2.2; GGT) in the periplasm.<sup>(38)</sup> *H. pylori* GGT catalyzes the transpeptidation and hydrolysis of the γ-glutamyl groups of glutamine and glutathione. Interestingly, these findings indicate that *H. pylori* GGT performs 2 functions. First, GGT functions in the physiological functioning of *H. pylori*. *H. pylori* is unable to take up extracellular glutamine and glutathione directly; GGT hydrolyzes these substances to glutamate. The glutamate is then transported into *H. pylori* cells via a Na<sup>+</sup>-dependent reaction and is mainly incorporated into the TCA cycle.<sup>(39)</sup> Second, GGT acts as a virulence factor by disrupting the antioxidant ability of host cells. Although glutathione has antioxidant potential in host cells, *H. pylori* GGT reduces extracellular glutathione levels. In fact, *H. pylori* GGT reduces the ROS resistance of the host cells and induces apoptosis or necrosis.<sup>(38,40)</sup>

Excess ROS are produced in *H. pylori*-colonized human stomachs; this induces oxidative stress to both the gastric mucosa and *H. pylori*. Because *H. pylori* has a deft capability of detoxifying ROS using a variety of enzymes to establish long-term colonization, (12,13) excess ROS leads solely to host cell damage.

## Oxidative Stress in the Progression of Gastric Motility Disorders

Gastric motility disorders can occur in many clinical settings with a wide variety in the severity of symptoms with or without gastric mucosal injuries. Gastric motility disorders are attributable to either damage within the smooth muscle itself or dysfunctions within the neuromuscular components including the enteric nerves and interstitial cells of Cajal (ICC), which regulate smooth muscle function. How oxidative stress is involved in these dysfunctions is discussed in the following situations.

### **Gastrointestinal Complications in Sepsis**

Oxygen radicals are implicated as relevant mediators in sepsis and septic shock in animals including humans. (41.42) Sepsis is a systemic response caused by bacterial endotoxins such as lipopolysaccharide, which induce the release of ROS and the generation of numerous pro-inflammatory factors and nitric oxide. During sepsis, the most frequent complications within the gastrointestinal tract are gastrointestinal motility disturbances and mucosal barrier dysfunction. Experimental administration of LPS delays gastric emptying and upregulates inducible nitric oxide synthase in order

to downregulate neuronal nitric oxide synthase (nNOS) and synthesize PGs. (43) It is also reported that SOD reverses the endotoxin-induced delay in gastric emptying and diminishes the presence of nitrotyrosine, 4-hydroxy-2-nonenal in gastric mucosa, and inducible nitric oxide synthase-positive residential macrophages in the external musculature; these suggest the involvement of oxidative and nitrosative stresses in the pathogenesis of lipopolysaccharide-induced gastrointestinal dysmotility. (44)

# Gastrointestinal Complications in Ischemia/Reperfusion Injury

The gastrointestinal tract is one of the most susceptible organ systems to ischemia. Previous investigations demonstrate that ischemia/reperfusion is a major contributor to gastric mucosal injury caused by stresses such as burn stress or hemorrhagic shock, NSAIDs, and H. pylori infection. In addition to mucosal injuries, delayed gastric emptying is also reported after gastric ischemia/reperfusion associated with disruption of the ICC network and nNOS-positive neurons. (45) ICC play critical roles in gastrointestinal motility in that they are the source of the electrical slow waves underlying the phasic contractions of the gastric musculature and mediate excitatory and inhibitory inputs to the musculature from the enteric motor neurons. Neuronal NOS generates neuronally derived NO, which is the major inhibitory neurotransmitter in the gastrointestinal tract. ICC and nNOS-positive neurons are both important factors for gastric emptying. Oxidative stress produced by the xanthine-xanthine oxidase system after ischemia/reperfusion may play a major role in these events, although the precise mechanism is unclear.

#### **Diabetes Mellitus**

Oxidative stress is a strong pathogenic co-factor involved in the development of complications of diabetes. Increased glucose levels in diabetes react non-enzymatically with proteins and become advanced glycation end products (AGEs); AGEs activate endothelial NADPH oxidase and increase endothelial ROS, (46) which occurs in animal models of diabetes(47) and diabetes patients. (48) Gastric neuromuscular dysfunction occurs in up to 30-50% of patients after 10 years of type 1 or 2 diabetes associated with histological changes including the loss of nNOS and ICC in both humans and animal models. It is reported that increased oxidative stress is attributable to the loss of upregulation of heme oxygenase-1; this results in the loss of ICC, decreased nNOS expression, and delayed gastric emptying in non-obese diabetic mice. These changes can be reversed by heme oxygenase-1 induction, demonstrating an important role of oxidative stress in the development of diabetic gastroparesis. (49)

### **Aging and Oxidative Stress**

Gastrointestinal function declines with aging, including delayed gastric emptying, decreased peristalsis, and slowed colonic transit; these impair quality of life and increase morbidity and mortality. Notable changes in gut neuromuscular function that accompany advanced age are reported in human and animal models. (50,51) Cowen et al. (52) report a 50% reduction in ileal myenteric neurons in 24-month-old Sprague-Dawley rats fed ad libitum; this was prevented by caloric restriction, which reduces oxidative stress. (53) In the study using progeric mice deficient in the anti-aging peptide Klotho, progeric mice exhibited a gastric phenotype resembling that of human aging involving profound ICC loss with reduced slow wave amplitude and nitrergic inhibitory junction potentials. Klotho protects ICC by preserving their precursors, limiting oxidative stress, and maintaining nutritional status and normal levels of trophic factors important for ICC differentiation. (54) Increased oxidative stress in combination with a decrease

> J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 37 ©2012 JCBN